A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
A-PREDICT is a study of axitinib in patients with metastatic renal cell carcinoma unsuitable
for nephrectomy (as judged by the treating clinician) to evaluate efficacy, safety, toxicity
and changes in biomarkers during therapy. Axitinib will given twice daily by mouth according
to tolerability of treatment, for as long as patients are deriving clinical benefit. Blood
and tumour tissue samples will be taken prior to and during therapy to evaluate biomarkers of
treatment response. The primary clinical objective of this study is to define the activity of
axitinib given to patients with metastatic renal cell carcinoma unsuitable for nephrectomy.